TNGX Tango Therapeutics, Inc.
FY2025 10-K
Tango Therapeutics, Inc. (TNGX) filed its fiscal year 2025 10-K annual report with the SEC on Mar 5, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Risk Factors
- • Regulatory risk: FDA clinical trial approvals and safety profiling of PRMT5 inhibitors vopimetostat and TNG456 ongoing with multiple Phase 1/2 trials active in 2026
- • Macroeconomic exposure: Cash runway of $343.1M as of Dec 31, 2025 expected to fund operations only into 2028, requiring substantial additional capital raises
Financial SummaryXBRL
Revenue
$62M
Net Income
-$102M
Operating Margin
-178.4%
Net Margin
-162.9%
ROE
-29.3%
Total Assets
$399M
EPS (Diluted)
$-0.87
Operating Cash Flow
-$139M
Source: XBRL data from Tango Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Tango Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.